Related Experiment Videos
Direct amifostine effect on renal tubule cells in rats
K J Weichert-Jacobsen1, A Bannowski, F Küppers
1Department of Urology, Medical School, Christian Albrechts University, Kiel, Germany.
Abstract:
Clinical trials indicate that amifostine offers protection against cisplatin-induced nephrotoxicity. It is unclear whether a direct pharmacological t on renal tubular cells is involved. We investigated the effect of amifostine pretreatment on the tubular apparatus and evaluated its nephroprotective potential. A total of 32 rats were treated by i.p. administration of 0.9% saline solution (group 1), 5 mg/kg cisplatin (group 2), 25 mg/kg amifostine (group 3), and 25 mg/kg amifostine followed by 5 mg/kg cisplatin (group 4) after 30 min. We recorded elevation of N-acetyl-beta-D-glucosaminidase (NAG) in 24 h pooled urine as a specific marker for tubular lesions, renal leakage of magnesium as an unspecific nephrotoxicity marker, and survival over a 10-day observation period. A significant (P < 0.002) increase in urinary NAG after treatment was documented only in cisplatin-treated group 2 [day 2 (mean+/-SE), 93+/-2.1 units/gram creatinine; day 4, 70.6+/-16 units/gram creatinine; normalization at day 8]. Treatment with amifostine before cisplatin administration resulted in a slight urinary NAG leakage (day 2, 2.8+/-1.8 units/gram creatinine; day 4, 13.8+/-13 units/gram creatinine; normalization at day 6). No increase in urinary enzyme levels was seen in the other groups, and there were no significant differences in urinary magnesium between all groups. Four of eight rats in the cisplatin-treated group and one of eight rats in the amifostine plus cisplatin-treated group died.
Insights
Amifostine pretreatment significantly reduced cisplatin-induced kidney damage in rats, indicated by lower N-acetyl-beta-D-glucosaminidase (NAG) levels. This suggests amifostine
Area of Science:
- Nephrology
- Pharmacology
- Toxicology
Background:
- Clinical studies suggest amifostine protects against cisplatin-induced nephrotoxicity.
- The precise mechanism of amifostine's protective effect on renal tubular cells remains unclear.
Purpose of the Study:
- To investigate amifostine's effect on the renal tubular apparatus.
- To evaluate the nephroprotective potential of amifostine pretreatment against cisplatin.
Main Methods:
- 32 rats were divided into four groups: saline control, cisplatin, amifostine, and amifostine followed by cisplatin.
- Urinary N-acetyl-beta-D-glucosaminidase (NAG) and magnesium levels were measured as markers of tubular damage and nephrotoxicity.
- Animal survival was monitored over a 10-day period.
Main Results:
- Cisplatin administration significantly increased urinary NAG levels, indicating tubular damage.
- Amifostine pretreatment before cisplatin resulted in only slight urinary NAG leakage.
- No significant differences in urinary magnesium were observed between groups, and survival rates improved with amifostine pretreatment.
Conclusions:
- Amifostine pretreatment demonstrates nephroprotective effects against cisplatin-induced renal tubular injury.
- The study supports amifostine's potential role in mitigating chemotherapy-induced kidney damage.
- Further research is warranted to elucidate the exact pharmacological mechanisms involved.